Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CELive EventsScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Richard D. Hall, MD

Advertisement

Articles by Richard D. Hall, MD

Dr. Hall on Combination Approaches in Advanced NSCLC

ByRichard D. Hall, MD
August 22nd 2018

Richard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).

Advertisement

Latest Updated Articles

  • Dr. Hall on Combination Approaches in Advanced NSCLC
    Dr. Hall on Combination Approaches in Advanced NSCLC

    August 22nd 2018



Advertisement
Advertisement

Trending on OncLive

1

First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian Cancer

2

LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

3

Dr Traina on Integrating T-DXd and Biomarkers Into Early-Stage HER2-Positive Breast Cancer Care

4

Dr Borgen on Matching Treatment to HER2 Biology in Early-Stage HER2-Positive Breast Cancer

5

Sonrotoclax-Based Regimens Elicit Responses in Relapsed/Refractory MCL

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us